Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)

2018-03-07T22:46:39-05:00

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)  --Data demonstrates that therapeutic targeting of the AID/RAD51 axis in B cells may block development of T1D by converting B cells to a suppressive population capable of inhibiting disease development --  --First demonstration of synthetic lethal pairs in a [...]